Indoco Remedies Secures USFDA Approval for Brivaracetam Oral Solution

Indoco Remedies Limited announced on February 24, 2026, that it received final approval from the USFDA for its Brivaracetam Oral Solution. The company's turnover stands at US$180 million.

Reader Takeaway: USFDA approval opens US market for generics; intense competition remains a pressure point.

What just happened (today’s filing)

Indoco Remedies Limited has obtained final approval from the United States Food and Drug Administration (USFDA) for its Brivaracetam Oral Solution. [cite: INPUT]

This approval allows the company to market a generic version of UCB Inc.'s Briviact, an antiepileptic medication used to treat partial-onset seizures. [cite: INPUT]

The drug will be manufactured at Indoco's facility located in the Verna Industrial Area, Goa.

This milestone signifies Indoco's expanding presence in regulated markets and its contribution to affordable global healthcare.

Why this matters

The USFDA nod is a significant step for Indoco, enabling it to tap into the lucrative US market for antiepileptic drugs.

It reinforces the company's capability in developing and manufacturing complex generic formulations, aligning with its strategy to grow in regulated markets.

This launch is expected to enhance Indoco's product portfolio and market reach, potentially contributing to revenue growth.

The backstory (grounded)

Indoco Remedies is a well-established, integrated pharmaceutical company with a global presence, focusing on both formulations and APIs.

It operates multiple USFDA-approved manufacturing facilities, underscoring its commitment to international quality standards.

The company has been actively seeking approvals for complex generics, aiming to build a robust portfolio for regulated markets.

In January 2026, Indoco had received USFDA approval for Lacosamide Oral Solution, another antiepileptic drug and a generic of UCB Inc.'s Vimpat.

What changes now

• Indoco Remedies can now legally market and sell Brivaracetam Oral Solution in the United States.
• The approval expands Indoco's generic product offerings in the crucial North American market.
• It validates the company's R&D and manufacturing capabilities for complex dosage forms.
• This is expected to bolster Indoco's revenue streams from regulated markets.

Risks to watch

• The generic pharmaceutical market is highly competitive, with potential for aggressive pricing strategies from rivals.
• Indoco's operations face inherent regulatory risks due to the stringent oversight by agencies like the USFDA, and pricing controls in domestic markets.
• Post-approval, successful market penetration and sales performance will depend on factors like product differentiation and marketing effectiveness.

Peer comparison

Lupin Ltd received USFDA approval for Brivaracetam tablets in December 2022, indicating existing generic competition for Briviact.

Alembic Pharmaceuticals has a strong track record with USFDA approvals for various epilepsy drugs, including Divalproex Sodium and Carbamazepine, with significant market sizes.

Sun Pharma's research arm obtained USFDA approval for an epilepsy drug (Lacosamide) back in 2015, showcasing early entry by Indian firms into this segment.

Context metrics (time-bound)

• Indoco Remedies reported a turnover of approximately US$180 million as of its latest available financial reports. [cite: 9, 11, INPUT]
• The Brivaracetam tablets (generic Briviact) market in the US had estimated annual sales of USD 420 million as of September 2022.

What to track next

• Indoco's launch timeline and initial sales figures for Brivaracetam Oral Solution in the US.
• Market uptake and any patent challenges or exclusivity periods related to the product.
• Performance of Indoco's existing US-approved products and pipeline developments.
• Any impact on Indoco's financial performance, particularly revenue growth from international markets.
• Future USFDA approvals for Indoco's complex generic pipeline.